These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22069022)

  • 1. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation.
    Baars JE; Nuij VJ; Oldenburg B; Kuipers EJ; van der Woude CJ
    Inflamm Bowel Dis; 2012 Sep; 18(9):1634-40. PubMed ID: 22069022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis.
    Li Y; Nuij VJ; Baars JE; Biermann K; Kuipers EJ; Peppelenbosch MP; de Haar C; Janneke van der Woude C
    Inflamm Bowel Dis; 2013 Jan; 19(1):132-40. PubMed ID: 22535619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.
    Bryant RV; Winer S; Travis SP; Riddell RH
    J Crohns Colitis; 2014 Dec; 8(12):1582-97. PubMed ID: 25267173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.
    Falvey JD; Hoskin T; Meijer B; Ashcroft A; Walmsley R; Day AS; Gearry RB
    Inflamm Bowel Dis; 2015 Apr; 21(4):824-31. PubMed ID: 25738372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeat endoscopy affects patient management in pediatric inflammatory bowel disease.
    Thakkar K; Lucia CJ; Ferry GD; McDuffie A; Watson K; Tsou M; Gilger MA
    Am J Gastroenterol; 2009 Mar; 104(3):722-7. PubMed ID: 19209163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal healing and clinical remission in inflammatory bowel diseases: are we missing something here?
    Sorrentino D
    Inflamm Bowel Dis; 2013; 19(4):E55-6. PubMed ID: 22517503
    [No Abstract]   [Full Text] [Related]  

  • 14. [Diagnostic problems of histological remission in patients with inflammatory bowel disease].
    Tertychnyi AS; Akhrieva KM; Maev IV; Zayratyants OV; Selivanova LS
    Arkh Patol; 2017; 79(3):3-9. PubMed ID: 28631710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory bowel disease in children--clinical, endoscopic, radiologic and histopathologic investigation.
    Seo JK; Yeon KM; Chi JG
    J Korean Med Sci; 1992 Sep; 7(3):221-35. PubMed ID: 1285921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: results from a randomized controlled trial.
    Baars JE; Vogelaar L; Wolfhagen FH; Biermann K; Kuipers EJ; van der Woude CJ
    J Crohns Colitis; 2010 Dec; 4(6):661-8. PubMed ID: 21122577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic features and genetic background of inflammatory bowel disease complicated with Takayasu arteritis.
    Akiyama S; Fujii T; Matsuoka K; Yusuke E; Negi M; Takenaka K; Nagahori M; Ohtsuka K; Isobe M; Watanabe M
    J Gastroenterol Hepatol; 2017 May; 32(5):1011-1017. PubMed ID: 28449344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
    Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
    Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.